Skip to main content

Table 3 Treatment Patterns of Patients with AD (Entire Observation Period)

From: Effects of variations in access to care for children with atopic dermatitis

  Medicaid
n = 240,648
Commercial
n = 236,836
P-value
Filled prescriptions per year, mean ± SD | median 3.3 ± 4.3 | 1.8 2.0 ± 2.8 | 1.0 <0.001*
  ≤1 prescription, n (%) 75,572 (31.4) 120,996 (51.1) <0.001*
 2–3 prescriptions, n (%) 87,804 (36.5) 73,057 (30.8) <0.001*
  >3 prescriptions, n (%) 77,272 (32.1) 42,783 (18.1) <0.001*
Combination therapy with ≥2 distinct AD treatments, n (%) 97,366 (40.5) 46,171 (19.5) <0.001*
Topical treatments, n (%) 210,857 (87.6) 203,975 (86.1) <0.001*
 Topical antihistamines 24 (0.0) 55 (0.0) <0.001*
 Any topical corticosteroids (TCS) 210,094 (87.3) 200,975 (84.9) <0.001*
  TCS low potency 100,439 (41.7) 74,010 (31.2) <0.001*
  TCS medium potency 158,484 (65.9) 147,297 (62.2) <0.001*
  TCS high potency 31,084 (12.9) 38,999 (16.5) <0.001*
 Topical calcineurin inhibitors (TCI) 7998 (3.3) 17,579 (7.4) <0.001*
Systemic antihistaminesa 170,511 (70.9) 51,817 (21.9) <0.001*
  ≥1 sedating antihistamine 78,319 (32.5) 37,094 (15.7) <0.001*
Systemic corticosteroids (SCS)b 54,878 (22.8) 59,626 (25.2) <0.001*
Any systemic immunosuppressants (IMM) 476 (0.2) 630 (0.3) <0.001*
 Azathioprine 54 (0.0) 93 (0.0) <0.001*
 Cyclosporine A 85 (0.0) 167 (0.1) <0.001*
 Interferon gamma 0 (0.0) 1 (0.0)
 Methotrexate 261 (0.1) 339 (0.1) <0.001*
 Mycophenolate mofetil 140 (0.1) 136 (0.1) 0.914
Intravenous immunoglobulin (IVIG) 2339 (1.0) 2784 (1.2) <0.001*
Montelukast sodiumc 37,719 (15.7) 39,810 (16.8) <0.001*
Phototherapy, n (%) 416 (0.2) 522 (0.2) <0.001*
  1. Notes
  2. AD atopic dermatitis, SD standard deviation
  3. aThe proportion of patients without comorbid asthma or allergies was 60.3% and 67.5% among Medicaid and Commercial patients prescribed systemic antihistamines, respectively
  4. bThe proportion of patients without comorbid asthma or allergies was 45.8% and 56.4% among Medicaid and Commercial patients prescribed SCS, respectively
  5. cThe proportion of patients without comorbid asthma or allergies was 35.3% and 46.9% among Medicaid and Commercial patients prescribed montelukast sodium, respectively
  6. *P-value< 0.05. P-values were calculated using Chi-square tests for categorical variables, and Wilcoxon Mann-Whitney test for continuous variables